# Pacific Biosciences of California Inc. (PACB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1.35, market value $420 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Pacific Biosciences of California Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Free-cash-flow yield: -29.5%** (5-yr avg -17.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 36.4%**. Pacific Biosciences of California Inc. keeps 36.4% of revenue after the direct cost of what it sells.
- **Operating margin: -83.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -341.5%**. The company reported a net loss over the last twelve months.
- **Return on invested capital: -12.5%**. Return on all capital, debt included, is -12.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -16.8%**. Each dollar of assets produces -16.8% of profit.

## Growth
- **Revenue growth (1 yr): 3.9%** (3-yr 7.6%/yr, 5-yr 15.2%/yr). Revenue grew 3.9% over the last year, against 15.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -14.5%**. Earnings per share fell 14.5%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 5.15** (quick 5.15). Current assets cover the next year's liabilities 5.15 times.
- **Altman Z-score: -1.33**. A Z-score of -1.33 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Pacific Biosciences of California Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 8.9%** (YTD -27.8%, 3-mo -6.9%). The shares are up 8.9% over twelve months including dividends.
- **From 52-week high: -50.5%** (26.2% above the low). Trading 51% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 2.50** (volatility 89%). Beta of 2.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PACB · Page: https://foliofundamentals.com/stocks/pacb

Not investment advice.